Answers are grounded in this paper and cite their sources.
Case report shows remission achievement in pediatric ALK-positive ALCL with intensive care and targeted therapies, indicating treatment potential for relapsed disease.
Background: Anaplastic large cell lymphoma (ALCL) is an aggressive T-cell lymphoma that, rarely, can present with secondary haemophagocytic lymphohistiocytosis (HLH). Observation(s): A 6-year-old boy with ALK-positive ALCL and HLH required intensive care and chemotherapy, experienced multiple relapses, and ultimately achieved remission with crizotinib, ruxolitinib, dexamethasone, and allogeneic stem cell transplant. Conclusions: This case illustrates the clinical challenges of treating ALK-positive ALCL with concurrent HLH and highlights the role of targeted therapies. As molecular understanding of ALCL increases, integrating novel targeted agents may improve outcomes, particularly in relapsed or high-risk disease.
No takes yet. Share an insight, caveat, or question.
Catueno et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: